US 12,115,130 B2
Tablet having a two-dimensional identifier
Klaus Kühne, Berlin (DE); Helmut Kerschbaumer, Zürich (CH); Daniel Moldenhauer, Jena (DE); Alexander Ruckdäschel, Raleigh, NC (US); and Achim Schneeberger, Vienna (AT)
Assigned to Laxxon Medical AG, Stetten (CH); and Exentis Knowledge GmbH, Stetten (CH)
Filed by Laxxon Medical AG, Stetten (CH); and Exentis Knowledge GmbH, Stetten (CH)
Filed on Mar. 23, 2022, as Appl. No. 17/702,435.
Claims priority of application No. 10 2021 202 880.2 (DE), filed on Mar. 24, 2021.
Prior Publication US 2022/0304895 A1, Sep. 29, 2022
Int. Cl. A61J 3/00 (2006.01); A61K 9/20 (2006.01)
CPC A61J 3/007 (2013.01) [A61K 9/2072 (2013.01); A61J 2205/30 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A solid dosage form for active ingredient release, the solid dosage form contained in a tablet comprising:
a three-dimensional base body, wherein the three-dimensional base body comprises an active ingredient, and
a portion having a structure forming a two-dimensional identifier,
wherein the portion is integral with the three-dimensional base body.